All News

Hepatitis B (Keep)

AGA Guideline: Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals

d Jack Cush, MD

The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.

Read Article
exercise.workout.jpg

Young Males and Future Risk of MSK and Chronic Diseases

d Jack Cush, MD

A large cohort of 18-year-old Swedish males were followed longitudinally for cardiovascular, respiratory, and musculoskeletal outcomes.

Read Article
celebrex.jpg

Celecoxib Lowers Colon Cancer Recurrence Risk

d Jack Cush, MD

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that adding the drug celecoxib

Read Article
Lifestyle diet alcohol risk obesity

Proinflammatory Diet Increases Gout Risk

d MedPage Today

Some dietary habits are worse than others when it comes to gout risk for women, a large study indicated.

Read Article
as.sacroiliitis.jpg

Infectious Sacroiliitis

d Jack Cush, MD

A large Chinese cohort study of patients with infectious sacroiliitis (SI) suggests that CT-guided biopsy of the sacroiliac joint is necessary to properly identify the infectious pathogen leading to SI.

Read Article
orthotics,afo

Orthotics in Rheumatoid Arthritis

d Bita Imam, DO, PhD,  , Andres Quiceno, MD

Orthotics are cost-effective, externally applied devices designed to stabilize the joints and provide a conservative measure to alleviate joint pain and improve function. Options include therapeutic shoes, shoe inserts, hand splints/braces, wrist support and finger splints. This article reviews some of the indications on the use of orthotics in patients with RA.

Read Article
QD clinics - lessons from the Clinic brought to you by RheumNow Live 2025 https://t.co/REMEN3gIjo https://t.co/P676QhAKwT

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Applauds Second Round of Medicare Drug Price Negotiations The ACR applauded the announcement of additional drugs subject to pricing negotiations with the CMS. This second round includes nintedanib (Ofev) and apremilast (Otezla), which are used to treat common and rare… https://t.co/z1LkpWMXqg https://t.co/hqjkqTqJxw
Dr. John Cush RheumNow ( View Tweet)
SubAnalysis of STOP Gout Trial: 277 pts w/ CKD received either allopurinol or febuxostat. Most achieved SUA goal (79% vs 81%), fewer allopurinol pts had gout flares (32% vs 45%; P=0.02); AKI only seen stage w/ 3 CKD (allopurinol > febuxostat) https://t.co/wwfVCei4Ej https://t.co/W8Y7KxcSd4

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of 39 imaging studies (12 MRI, 26 evaluated ultrasound) in pts w/ clinically suspect arthralgia showed variable results for imaging predicting progression from CSA to inflamm. arthritis (RA). US sensitivity/specificity = 37%/90%; MRI was 45%/84% https://t.co/uUl5i2t7ib https://t.co/ScnA7aN07N

Links:

Dr. John Cush RheumNow ( View Tweet)
NIH study of MSK disease burden finds research on neck pain as most underfunded (0.83%) followed by LBP (13.9%), OA (35.1%) & RA (66.3%) - NIAMS is low compared to other institutes. In USA, MSK dz affect 1 in 3 people, approximately 127.4 million individuals.… https://t.co/MqU9TsY6GR https://t.co/rRvUYc2yee
Dr. John Cush RheumNow ( View Tweet)
NHANES survey data on 2200 #RA pts shows dietary modification can yield reduced all-cause mortality risk. Diets w/ high Healthy Eating Index & low Dietary Inflammatory Index (DII) reduced mortality (HR 0.70; 95% CI: 0.53–0.92; adjusted P = 0.01) https://t.co/T77YQMvRQ2 https://t.co/WaCapITHGK

Links:

Dr. John Cush RheumNow ( View Tweet)
North American Real-world EHR data of PsA & axSpA pts (n 2200 Ea.) found no higher rates of CVD (acute MI, CVA or revascularization) or solid cancers (breast, colorectal, lung, prostate) when comparing JAKi to either TNFi or IL-17i use (over 3 years). https://t.co/macjpWxdnY https://t.co/9gXiomU3YD

Links:

Dr. John Cush RheumNow ( View Tweet)
German database shows since 2010, work participation has improved for rheum pts, reflected in higher employment, reduced absenteeism and less disability retirement. However, patients have not reached population employment rates. https://t.co/B8VKBgGNGe https://t.co/OOMNym3XrR

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic- Past Diagnoses When patients cling to a past diagnosis. Features Dr. Jack Cush. QD Clinics - lessons from the clinic Sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6 https://t.co/EB21WTDPJ2 https://t.co/JK4i2et8at

Links:

Dr. John Cush RheumNow ( View Tweet)
Weak Data (1.24.2025) Dr. Jack Cush reviews the news and journal reports from https://t.co/V10S4oVFsv. He features Dr. Charity Dean, the Keynote speaker at RheumNow Live 2025 and why she is an inspiration. https://t.co/RKMvWVVnJA https://t.co/hmaPNZ9S5A

Links:

Dr. John Cush RheumNow ( View Tweet)
Quick study of Henoch-Schönlein Purpura (HSP) in Children: An Overview https://t.co/n4V0XfMYbA https://t.co/zJ5WVjdfYe

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - An Undiagnosed Autoinflammatory Patient Autoinflammatory or Still's disease - does this matter? Features Dr. Jack Cush. QD Clinics - lessons from the clinic Sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6… https://t.co/UimGBUZMeO https://t.co/fkAg9gK0Im

Links:

Dr. John Cush RheumNow ( View Tweet)
Open label trial of starting MTX in 11 uncontrolled gout pts previously Rx w/ IV pegloticase (PEG 2-27x) showed if gout pts failed PEG monotherapy, only 1/11 (9%) showed a good response to adding MTX w/ PEG. MTX must be started w/ PEG initiation to work https://t.co/aoBtyIRbQe https://t.co/RNe03O6Z1N

Links:

Dr. John Cush RheumNow ( View Tweet)
Febuxostat (ULORIC) is discontinued by the manufacturer in the USA. This week an FDA update on drug shortages list announced Uloric has been discontinued. Takeda sited dropping sales, generic competition, and CV safety concerns in the last decade. GENERIC febuxostat should still… https://t.co/QcUNCUFfvJ https://t.co/oBdwkcN177
Dr. John Cush RheumNow ( View Tweet)
×